RESUMO O controle do mosquito Aedes aegypti, vetor de patógenos causadores da dengue, Zika e chikungunya é prioritário, e sensibilizar a população quanto à prevenção, através de práticas educativas, pode impactar na redução do número de casos. Dentre essas práticas, existem propostas que exploram a ludicidade, incluindo o uso de jogos de tabuleiro educativos. O presente trabalho analisou cinco propostas ludopedagógicas com jogos de tabuleiro, publicadas entre 2015 e 2019, e concluiu que apesar de 40% dos trabalhos demonstrarem preocupação em escutar os alunos, as abordagens priorizam a memorização de conteúdos factuais e procedimentais. Além disso, as propostas demonstram baixo letramento lúdico nos professores e alunos envolvidos nas pesquisas.

ABSTRACT Controlling Aedes aegypti, the vector of pathogens that cause dengue, Zika and chikungunya is a priority, and raising the awareness of the population about prevention, through educational practices, may reduce the number of cases of these diseases. One of these practices is the use of educational board games. The present study analyzed five playful pedagogical proposals with board games, published between 2015 and 2019, and concluded that although 40% of the studies listen to the students, the approaches prioritize the memorization of factual and procedural contents. In addition, the proposals demonstrate the low playful literacy of the teachers and students involved in the research.

The Bacille Calmette-Guérin (BCG) vaccine comprises a family of genetically different strains derived by the loss of genomic regions (RDs) and other mutations. In BCG Moreau, loss of RD16 inactivates rv3405c * , encoding a transcriptional repressor that negatively regulates the expression of Rv3406, an alkyl sulfatase. To evaluate the impact of this loss on the BCG and host cell viability and the cytokine profile, THP-1 cells were infected with BCG Moreau (harbouring the empty vector) and a complemented strain carrying a functional copy of rv3405c. Viability of the host cells and bacteria as well as the pattern of cytokine secretion were evaluated. Our results show that the viability of BCG Moreau is higher than that of the complemented strain in an axenic medium, suggesting a possible functional gain associated with the constitutive expression of Rv3406. Viability of the host cells did not vary significantly between recombinant strains, but differences in the profiles of the cytokine secretion (IL-1β and IL-6) were observed. Our results suggest an example of a functional gain due to gene loss contributing to the elucidation of the impact of RD16 on the physiology of BCG Moreau.

The bacillus Calmette-Guérin (BCG) vaccine is the only licensed vaccine for human use against tuberculosis (TB). Although controversy exists about its efficacy, the BCG vaccine is able to protect newborns and children against disseminated forms of TB, but fails to protect adults against active forms of TB. In the last few years, interest in the mucosal delivery route for the vaccine has been increasing owing to its increased capacity to induce protective immune responses both in the mucosal and the systemic immune compartments. Here, we show the importance of this route of vaccination in newly developed vaccines, especially for vaccines against TB.

The vaccine Bacillus of Calmette Guérin (BCG) was originally developed in France as an oral vaccine against tuberculosis. The oral use of this vaccine was replaced by the parenteral route in almost all countries after the Lubeck disaster. In contrast, Brazil retained the oral delivery of the vaccine until the mid-seventies when it was replaced by the intradermal route. This change in route of delivery was mainly secondary to pressure by medical practitioners based on the poor responses of oral immunized subjects to purified protein derivative (PPD) skin tests. Even after the change of route of delivery, Ataulpho de Paiva Foundation continued making the oral vaccine. Currently, BCG Moreau has been described as one of the most immunogenic and with fewer side effects than other BCGs. The genomics, proteomics and vaccine trials for oral BCG Moreau Rio de Janeiro are currently under investigation. In this review, we intend to describe the history of BCG Moreau Rio de Janeiro in Brazil.